Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab-IRDye800 for Optical Imaging of Intracranial Lesions
NCT07493447Phase 1Recruiting
- Sponsor
- Eben Rosenthal
- Start
- Jul 2026
- Primary completion
- May 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of panitumumab-IRDye800CW (2 arms), sponsored by Eben Rosenthal. Primary endpoint: Safety of panitumumab-IRDye800 at 15 days. Started Jul 2026; status: recruiting.
02
Drugs
panitumumab-IRDye800CW
Beyond the preview
Go deeper on NCT07493447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493447.